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LeptinAbstract Background: Cardiovascular diseases (CVD) and atherosclerosis are over presented in
patients with systemic lupus erythematosus (SLE).
Aim of the work: The aim of this study is to determine the frequency of some atherosclerosis
biomarkers in SLE patients with and without CVD compared with controls.
Patients and methods: 28 female SLE patients with a mean age of 30.1 ± 7.2 years and a history
of CVD (SLE cases) were compared with 25 age matched SLE female patients but without a history
of CVD (SLE controls) and 25 age matched population based control women (population controls).
Intima, media thickness (IMT) was measured by B-mode ultrasound as a potential measure of
atherosclerosis. Nontraditional biomarkers of atherosclerosis such as leptin, oxidized LDL
(oxLDL) and homocysteine were also investigated.
Results: SLE cases had significantly increased IMT compared with SLE controls and population
controls (p< 0.001), whereas IMT of SLE controls did not differ from population controls. Com-
pared to SLE controls, SLE cases had raised circulating levels of leptin (p< 0.001), homocysteine,
dyslipidemia with raised triglycerides (p< 0.001), decreased HDL-cholesterol concentration,
(p< 0.001), lupus anticoagulants (p= 0.01), and higher cumulative prednisone dose (p= 0.4).
Disease duration was comparable between the two SLE groups and the blood pressure and body
mass index (BMI) were similar among the 3 groups.
Conclusion: A set of distinct CVD risk factors (biomarkers of atherosclerosis) separate SLE
cases from SLE controls and normal population controls. If confirmed in a prospective study, they
could be used to identify SLE patients at high risk of CVD in order to optimize treatment.
 2016 Egyptian Society of Rheumatic Diseases. Production and hosting by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).ular dis-
2 N. Khairy et al.1. Introduction
Patients with systemic lupus erythematosus (SLE) have a sig-
nificantly increased risk of cardiovascular morbidity and
mortality, particularly related to premature atherosclerosis
(AS). Oxidized LDL (oxLDL) plays an important role in
atherogenesis and may contribute to the immune activation
and inflammation present in the atherosclerotic lesions,
because it has chemotactic, immune-stimulatory, and toxic
properties and is taken up by macrophages and other cells
in the atherosclerotic plaque, which develop into foam cells
[1–6].
Although traditional cardiac risk factors, such as older age,
high blood pressure (BP), high cholesterol and triglycerides,
smoking, obesity, diabetes mellitus, appear to play a critical
role in the determinism of AS, these factors alone cannot
adequately explain the increased incidence of cardiovascular
disease commonly reported in patients with SLE [1,3]. In
Egyptian SLE patients, metabolic syndrome was considered
a remarkable risk factor for the development of subclinical
atherosclerosis and increased carotid intima-media thickness
(IMT) [7–9]. Accordingly, early accelerated AS in SLE is the
result of complex cross talk between the usual traditional
cardiac risk factors and non-traditional SLE biomarkers of
inflammation [1,3,4].
The non-traditional AS biomarkers included both leptin
and homocysteine, where leptin acts on the immune system
as a proinflammatory cytokine. In animal models, its defi-
ciency is associated with an increased susceptibility to infection
and reducing the inflammation [10]. It promotes the prolifera-
tion and activation of T lymphocytes and induces production
of Th1 cytokines [11–13]. Studies have reported increased
leptin levels in SLE patients [14,15]. On the other hand studies
stated that homocysteine levels are predictors for the develop-
ment of coronary artery disease (CAD) and the occurrence of
stroke in the general population. In addition, homocysteine
levels have been identified as a predictor of atherosclerosis in
patients with SLE, in whom high levels may be predictive levels
of coronary calcification [16], platelet progression [17] and
increased IMT [7,18].
The aim of this study was to determine the frequency of
some of the atherosclerosis biomarkers in SLE patients with
and without CVD to develop an early screening tool for the
identification of high risk SLE patients.2. Patients and methods
2.1. Study population
We have enrolled 53 SLE patients fulfilling the 1982 revised
criteria of the American Rheumatism Association for the clas-
sification of SLE [19], with a mean age of 30.5 ± 9.6 years and
mean disease duration of 3.6 ± 4.3 years, in addition to 25 age
matched healthy populations with a mean age of 30.4
± 7.1 years. The studied group was classified into two further
groups, group (I) which included 28 patients with a history of
CVD (SLE cases) and group (II) which included 25 age
matched SLE patients without history of CVD (SLE controls).
All subjects were informed about the aim of the study and gave
their consent. The study was approved by the local ethicsPlease cite this article in press as: Khairy N et al. Atherosclerosis biomarkers in fem
eases, The Egyptian Rheumatologist (2016), http://dx.doi.org/10.1016/j.ejr.2016.03.0committee. The control subjects were unrelated to patients
but were ethnically and socioeconomically similar. Physical
examinations for them were normal, with blood pressure
<135/85 mmHg, no urine abnormalities, and no history of
autoimmune or rheumatic disease or any other diseases with
a known genetic or hereditary predisposition.
All SLE patients were subjected to full history taking,
general examination, cardio pulmonary, abdominal, neurolog-
ical and locomotor systems examination. During routine
laboratory investigations (complete blood count, liver and
kidney functions by Jaffe kinetic method, and urine analysis),
High sensitivity C-reactive protein (hsCRP) was measured
using (latex-immunoturbidimetric method: <1 mg/L low risk,
1–3 mg/L medium risk, and >3 mg/L high risk). Immunological
assays (ANA and anti-DNA) were done by indirect
immunofluorescence and serum C3 and C4 levels by neph-
elometry (Beckman, USA). Twenty-four hour urine samples
were collected to estimate total urinary protein levels by the
colorimetric method. Blood and urine samples were always
collected on the same day. Detection of the anticardiolipin
(ACL) antibodies was done using the enzyme linked
immunosorbent assay (ELISA), while detection of lupus
anticoagulant was done using the dilute Russel viper venom
time (dRVVT) clotting assay.
Systemic hypertension was recorded when systolic
P140 mmHg and/or diastolic blood pressure P90 mmHg,
measured in multiple occasions or when antihypertensive med-
ication was taken. Dyslipidemia was defined as any of the fol-
lowing or in combination: raised low density lipoprotein
(LDL) cholesterol >130 mg/dl, total cholesterol >200 mg/dl,
triglycerides >150 mg/dl, or low level of high density lipopro-
tein (HDL) cholesterol <40 mg/dl. Diabetes mellitus was
defined either by fasting blood sugar >120 mg/dl or taking
insulin or hypoglycemic drugs. The global disease activity
was assessed by SLE disease activity index (SLEDAI) [20].
All patients were taking steroids (dose range 15–50 mg/day),
45 patients on hydroxychloroquine (dose range 200–400 mg/day),
25 patients on azathioprine (dose range 100–150 mg/day)
and 18 patients were receiving monthly cyclophosphamide
pulse therapy depending on extent of renal lesion (dose range
700–1000 mg).
2.2. Measurement of serum biomarkers
Clotted samples were stored at 20 C until the time of
analysis.
 Oxidized LDL was assayed using kit purchased from
immunodiagnostic AG (catalog No. K7810). That was a
sandwich ELIZA for direct measurement of oxLDL in
human serum. Standards, controls and samples containing
human oxLDL were added to wells of microplate that were
coated with high affinity antibodies. A dose response curve
of absorbance unit (optical density at 450 nm) versus
concentration was generated; using the values obtained
from standard. oxLDL present in the patient samples was
determined directly from this curve. Patients taking statins
in the past 3 months were excluded.
 Leptin was analyzed by leptin kit, (DRG instruments
GmbH, division of DRG International, Inc, Vers. 9.0,
Ref: EIA-2395, Germany) through ELIZA.ale systemic lupus erythematosus patients with and without cardiovascular dis-
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Table 1 Demographic, laboratory data, clinical manifesta-
tions and intima media thickness in SLE patients.
Parameter
mean ± SD or n (%)
SLE patients
(n= 53)
Demo graphic Age (years) 30.5 ± 9.6
Disease duration (years) 3.6 ± 4.3
BMI 26.5 ± 4.5
Steroid dose 24.4 ± 15.6
Laboratory data ESR (mm/1st hour) 71.6 ± 39.2
hsCRP (mg/L) 4.51 ± 8.13
Hemoglobin (g/dl) 12.4 ± 1.9
WBCs (103/mm3) 7.2 ± 3.8
Platelets (103/mm3) 223 ± 78.8
Serum creatinine (mg/dl) 1.8 ± 0.3
Serum albumin (gm/dl) 3.3 ± 0.8
Urine protein (gm/24 h) 1.2 ± 0.9
Cholesterol (mg/dl) 202.5 ± 47
Triglycerides (mg/dl) 170.6 ± 120.6
HDL (mg/dl) 60.1 ± 28.0
LDL (mg/dl) 140.9 ± 37.7
Leptin (ng/ml) 32.3 ± 24.2
Homocysteine (mmols/L) 16.85 ± 2.7
FBS (mg/dl) 94.2 ± 14.8
ACL antibodies 28 (52.8)
Lupus anticoagulant 21 (39.6)
b2GP IgG 8 (15.1)
Seropositive ANA 53 (100)
Anti-ds DNA 49 (92)
Clinical
manifestations
Fever 20 (37)
Malar rash 40 (75)
Photosensitivity 45 (85)
Alopecia 10 (18)
Oral ulcers 30 (56)
Vasculopathy 20 (37)
Hypertension 29 (54)
Arthritis 30 (56)
Nephritis 33 (62)
Serositis 39 (73)
Secondary APS 27 (50.9)
Raynauds phenomena 16 (30)
SLEDAI 20.1 ± 6.4
CIMT Right 5.8 ± 1.1
Left 5.7 ± 1.1
Carotid plaque 2 (3.8)
BMI: body mass index, ESR: erythrocyte sedimentation rate,
hsCRP: high sensitivity C-reactive protein, WBCs: white blood
cells, FBS: fasting blood sugar, ACL: anti cardiolipin, b2GP IgG:
beta-2 glycoprotein, ANA: anti-nuclear antibodies, Anti-ds DNA:
anti-double stranded, APS: antiphospholipid syndrome, SLEDAI:
Systemic Lupus Erythematosus Disease Activity Index. CIMT:
carotid intima media thickness.
Atherosclerosis biomarkers in female systemic lupus erythematosus patients 3 Homocysteine was analyzed by homocysteine kit, (DRG
instruments GmbH, division of DRG International, Inc,
Vers. 5.1, Ref: EIA-2925, Germany) through ELIZA.
Carotid intima media thickness (cIMT) was measured using
a B-mode ultrasound using automated Qlab software (Philips
Medical System) as a measurement of the presence of
atherosclerotic plaques. All ultrasound were performed by 4
registered vascular radiologists, who were trained to perform
the studies according to a preset protocol [21]. The same radi-
ologist interpreted all studies, and was blinded with regard to
the patients’ demographic characteristics, SLE status and any
previous ultrasound results. cIMT was assessed at three levels
on each side: common carotid artery (10 mm before the bulb),
bulb (5–10 mm cranially to the start of the bulb) and internal
carotid artery (10 mm after the flow divider); mean cIMT
(m-cIMT) was defined as the mean of the three cIMT measure-
ments on each side, while the maximum cIMT, the highest
cIMT value found among the six segments studied [22].
According to current sonographic criteria, we refer to
‘‘normal” cIMT when complex intima-media is <0.9 mm;
the cIMT >0.9 mm was considered indicative of thickened
intima, while >1.3 mm indicative of atherosclerotic plaque
[4,22]. Any history of CVD was detected by either a history
of myocardial infarction (MI) or a compensated CAD with
angiogram or stress test, history of cerebrovascular events
(CVE) included transient ischemic attacks (confirmed by a
physician) or stroke (confirmed by imaging).
2.3. Statistical method
The data were coded and entered using the statistical package
SPSS version 15. The data were summarized using descriptive
statistics: mean, standard deviation, median, minimal and
maximum values for quantitative variables and number and
percentage for qualitative values. Statistical differences
between groups were tested using Chi Square test for qualita-
tive variables, Student’s T test between 2 groups for quantita-
tive normally distributed variables while Nonparametric
Mann–Whitney test and Kruskal–Wallis test were used for
quantitative variables which are not normally distributed.
Correlations were done to test for linear relations between
variables. p-Values less than 0.05 were considered statistically
significant.
3. Results
3.1. Characteristics of the study groups
Fifty-three females with SLE; 28 with CVD (group 1) and 25
without (group 2) and 25 healthy female volunteers were
included in this study. The main demographic and clinical
features of the studied SLE patients are shown in Table 1.
3.2. Traditional risk factors
Disease duration, blood pressure, body mass index (BMI) and
diabetes did not differ between the two groups. On the other
hand there was a significant difference involving the hsCRP
and the ESR between the two SLE groups (p< 0.001 respec-
tively), in addition a significant difference was found betweenPlease cite this article in press as: Khairy N et al. Atherosclerosis biomarkers in fem
eases, The Egyptian Rheumatologist (2016), http://dx.doi.org/10.1016/j.ejr.2016.03.0SLE cases who had increased levels of both lupus anticoagu-
lants (p= 0.01), ACL antibodies (p= 0.006), higher cumula-
tive prednisone dose (p= 0.4) and SLEDAI score (0.001)
compared with SLE controls (without CVD).
3.3. Biomarkers of atherosclerosis
Carotid ultrasound has showed a thickened intima in about
30% of SLE patients, while carotid plaques have been demon-
strated in 3.8% of the SLE patients. SLE cases had increasedale systemic lupus erythematosus patients with and without cardiovascular dis-
03
Table 2 Comparison between the two SLE groups (with and without CVD) regarding demographic, laboratory and clinical
characteristics as well as the carotid IMT.
Parameters mean ± SD or n (%) SLE patients (n= 53)
Group (1) (n= 28) Group (2) (n= 25) p value
Demo graphic Disease duration (years) 4.4 ± 4.6 3.1 ± 3.9 0.2
Age (years) 30.9 ± 11.9 30.3 ± 7.9 0.8
BMI 27.9 ± 4.0 24.9 ± 4.6 0.015
Steroid dose (mg/d) 24.4 ± 15.6 28.3 ± 13.1 0.3
Laboratory data ESR (mm/h) 42.7 ± 24.5 35.3 ± 22.5 <0.001
hsCRP (mg/L) 12.8 ± 4.2 11.8 ± 3.4 <0.001
Hemoglobin (g/dL) 10.8 ± 2.3 10.1 ± 1.5 0.2
WBCs (103/mm3) 8.1 ± 4 6.5 ± 3.5 0.1
Platelets (103/mm3) 250.9 ± 71.7 204.4 ± 78.8 0.02
Creatinine (mg/dL) 1.3 ± 0.5 1.2 ± 0.6 <0.001
Cholesterol 270 ± 20.4 200 ± 18.5 <0.001
TGs (mg/dL) 200.3 ± 20.5 170.3 ± 18.5 <0.001
HDL (mg/dL) 47.5 ± 15.4 74.2 ± 32.2 0.001
LDL (mg/dL) 158.6 ± 29.5 121.1 ± 36.5 <0.001
Leptin (ng/mL) 70.3 ± 10.1 55.0 ± 7.8 <0.001
Homocysteine (lM/L) 20.3 ± 4.2 13.4 ± 1.2 <0.001
ANA 27 (96.4) 24 (96) 1.0
Anti ds-DNA 16 (57.1) 12 (48) 1.0
ACL 20 (71.4) 8 (32) 0.006
Lupus anticoagulants 16 (57) 5 (20) 0.01
b2GP 1 6 (21) 25 (8) 0.05
Low complement 18 (64) 10 (40%) 0.1
Clinical manifestations Hypertension 17 (60) 12 (48) 0.4
Diabetes 4 (14) 2 (8) 0.7
Psychosis 6 (21) 3 (12) 0.3
Serositis 18 (64) 17 (68) 0.2
Arthritis 10 (35) 9 (36) 0.6
Myositis 6 (21) 4 (16) 0.2
Vasculitis 2 (7) 3 (12) 0.4
Nephritis 11 (39) 17 (68) 0.06
APS 20 (71) 7 (28) 0.002
SLEDAI 21.7 ± 6.5 8.3 ± 6.2 0.001
CIMT (mm) 8.3 ± 0.7 4.5 ± 0.6 <0.001
BMI: body mass index, ESR: erythrocyte sedimentation rate, hsCRP: high sensitivity C-reactive protein, WBCs: white blood cells, TG:
triglycerides, HDL: high density lipoprotein, LDL: low density lipoprotein, ANA: anti-nuclear antibodies, Anti-ds DNA: anti-double stranded,
ACL: anti cardiolipin, b2GP IgG: beta-2 glycoprotein, APS: antiphospholipid syndrome, SLEDAI: Systemic Lupus Erythematosus Disease
Activity Index. CIMT: carotid intima media thickness.
4 N. Khairy et al.IMT compared with SLE controls (p< 0.001) and population
controls (p< 0.001), whereas IMT of SLE controls did not
differ from population controls. SLE cases had raised circulat-
ing levels of leptin (p< 0.001), homocysteine, dyslipidemia
with raised triglycerides (p< 0.001), decreased HDL-
cholesterol concentration (p< 0.001) compared with SLE
controls, in addition to a higher oxLDL level in SLE patients
than control population (p< 0.001) (Table 2).
4. Discussion
In this study, we investigated the biomarkers of atherosclerosis
in 53 SLE patients with and without CVD. The common car-
otid IMT of SLE cases was greater than those of SLE controls
and population controls, a finding that validates our selection
of patients and also indicates that subclinical atherosclerosis
plays an important role in arterial disease in SLE. The IMTPlease cite this article in press as: Khairy N et al. Atherosclerosis biomarkers in fem
eases, The Egyptian Rheumatologist (2016), http://dx.doi.org/10.1016/j.ejr.2016.03.0of SLE controls was not different from population controls.
The SLE cases tended to have more plaques than SLE con-
trols, and both SLE cases and SLE controls had significantly
more plaques than population controls. In addition, in the
SLE cases SLEDAI score had a significant difference to SLE
controls which is in conjunction with other studies that stated
that high damage score has been considered as an independent
predictor of carotid plaque [23,24].
Oxidized LDL has pro-inflammatory and atherogenic
properties [25]. It is possible that oxidized LDL may contribute
to arterial disease in SLE patients. In the present study, plasma
oxidized LDL was significantly enhanced in SLE cases than in
SLE controls and healthy controls whereas the latter two
groups were comparable. Our data were in line with several
studies which showed that Oxidized LDL predicts an increased
risk for MI, and its level is increased in young survivors of MI
[26–28].ale systemic lupus erythematosus patients with and without cardiovascular dis-
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by both arterial and venous thrombosis and is common in
SLE [29]. In this study, ACL, b2 glycoprotein antibodies and
lupus anticoagulants showed significant association with
CVD in SLE. It is possible therefore that the increased risk
of CVD in SLE is to some extent caused by thrombosis.
Homocysteine is increasingly recognized as a risk factor in
SLE. Homocysteine is thought to exert atherogenic effect
through oxidative damage and, induced oxidative stress caus-
ing endothelial dysfunction and lipid peroxidation [16–18]. In
our study homocysteine levels were higher in SLE patients
with CVD, while other studies have demonstrated no relation
between homocysteine and CVD in SLE patients [30,31].
Leptin is a proinflammatory cytokine that appears to con-
tribute to systemic inflammation in autoimmune rheumatic
diseases, including SLE [14,15]. McMahon et al. [3] had stated
that leptin levels were independently associated with carotid
plaque and positively correlated with oxidized phospholipids
in SLE patients. In the present study, leptin levels were
significantly higher in SLE cases when compared with the
SLE control group, a finding that was also observed in other
studies [15,32,33].
Steroid treatments are often believed to be atherogenic due
to its effect on plasma liproproteins and because inflammation
is implicated in atherogenesis. Our study showed that in spite
of the high cumulative prednisone dose, the SLE control group
did not have an increased common carotid intima media
thickness while SLE cases had an increased IMT.
In our current study hsCRP was significantly elevated in
SLE cases which coincides with other studies that showed
hsCRP as an independent predictor of thickened intima in
SLE patients [34,35].
Our study identifies a variety of risk factors for CVD in
SLE patients, not only traditional factors such as dyslipidemia
and diabetes but also a range of factors of acute and chronic
inflammation, including indices of enhanced LDL-oxidation,
leptin plasma levels and homocysteine. Larger prospective
studies are suggested to clarify and evaluate, whether these
factors can predict future CVD. If so, they can be used to
identify a high risk group that would be eligible for intense
intervention, with anti-oxidants and anti-inflammatory agents.Conflict of interest
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